Drugs / BAVUNALIMAB
BAVUNALIMAB
also known as
XmAb22841 · anti-CTLA-4/PD-1 expressing EGFR-CAR-T · Anti-CTLA-4/PD-1 expressing MUC1-CAR-T · Pavunalimab
Monoclonal antibody targets EGFR, LAG3, MUC1 via depletion
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05695898 | Feb 2023 → Apr 2024 | metastatic melanoma | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03849469 | May 2019 → Feb 2023 | anal squamous cell carcinoma, cervical carcinoma, endometrial carcinoma, fallopian tube carcinoma +15 | Xencor, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03182816 | Jun 2017 → Jan 2019 | neoplasm | Shanghai Cell Therapy Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT03179007 | Jun 2017 → Jan 2019 | cancer or benign tumor | Shanghai Cell Therapy Research Institute | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAVUNALIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095453 ↗ |
| Known as | anti-CTLA-4/PD-1 expressing EGFR-CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03182816 ↗ |
| Known as | Anti-CTLA-4/PD-1 expressing MUC1-CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03179007 ↗ |
| Known as | Pavunalimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095453 ↗ |
| Known as | XmAb22841 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03849469 ↗ |
| Action | Deplete | “MUC1-CAR-T can specificly and effectively kill the MUC1 positive cancer cells” NCT03179007 ↗ |
| Modality | Cell therapy | “CAR-T cells are cultured in a GMP standard workshop” NCT03179007 ↗ |
| Route | Intravenous | “receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells” NCT03179007 ↗ |
| Target | MUC1 | “chimeric antigen receptor targeting MUC1” NCT03179007 ↗ |